These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 33390479)
1. [Pharmacological and clinical profile of gilteritinib (Xospata Mori M; Hidaka K Nihon Yakurigaku Zasshi; 2021; 156(1):37-46. PubMed ID: 33390479 [TBL] [Abstract][Full Text] [Related]
2. The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation. Tzogani K; Røshol H; Olsen HH; Aas IB; Dalhus ML; Håkonsen GD; Nilssen LS; Lindberg V; Økvist M; Bolstad B; Rogovska I; Karpova N; Enzmann H; Gisselbrecht C; Pignatti F Oncologist; 2020 Jul; 25(7):e1070-e1076. PubMed ID: 32154636 [TBL] [Abstract][Full Text] [Related]
3. Gilteritinib or Chemotherapy for Relapsed or Refractory Perl AE; Martinelli G; Cortes JE; Neubauer A; Berman E; Paolini S; Montesinos P; Baer MR; Larson RA; Ustun C; Fabbiano F; Erba HP; Di Stasi A; Stuart R; Olin R; Kasner M; Ciceri F; Chou WC; Podoltsev N; Recher C; Yokoyama H; Hosono N; Yoon SS; Lee JH; Pardee T; Fathi AT; Liu C; Hasabou N; Liu X; Bahceci E; Levis MJ N Engl J Med; 2019 Oct; 381(18):1728-1740. PubMed ID: 31665578 [TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776 [TBL] [Abstract][Full Text] [Related]
6. The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia. Altman JK; Perl AE; Hill JE; Rosales M; Bahceci E; Levis MJ Cancer Med; 2021 Feb; 10(3):797-805. PubMed ID: 33340276 [TBL] [Abstract][Full Text] [Related]
7. Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia. Hosono N; Yokoyama H; Aotsuka N; Ando K; Iida H; Ishikawa T; Usuki K; Onozawa M; Kizaki M; Kubo K; Kuroda J; Kobayashi Y; Shimizu T; Chiba S; Nara M; Hata T; Hidaka M; Fujiwara SI; Maeda Y; Morita Y; Kusano M; Lu Q; Miyawaki S; Berrak E; Hasabou N; Naoe T Int J Clin Oncol; 2021 Nov; 26(11):2131-2141. PubMed ID: 34363558 [TBL] [Abstract][Full Text] [Related]
8. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy. Perl AE; Larson RA; Podoltsev NA; Strickland S; Wang ES; Atallah E; Schiller GJ; Martinelli G; Neubauer A; Sierra J; Montesinos P; Recher C; Yoon SS; Maeda Y; Hosono N; Onozawa M; Kato T; Kim HJ; Hasabou N; Nuthethi R; Tiu R; Levis MJ Transplant Cell Ther; 2023 Apr; 29(4):265.e1-265.e10. PubMed ID: 36526260 [TBL] [Abstract][Full Text] [Related]
9. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Mori M; Kaneko N; Ueno Y; Yamada M; Tanaka R; Saito R; Shimada I; Mori K; Kuromitsu S Invest New Drugs; 2017 Oct; 35(5):556-565. PubMed ID: 28516360 [TBL] [Abstract][Full Text] [Related]
10. Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a Ballesta-López O; Solana-Altabella A; Megías-Vericat JE; Martínez-Cuadrón D; Montesinos P Future Oncol; 2021 Jan; 17(2):215-227. PubMed ID: 32975130 [TBL] [Abstract][Full Text] [Related]
11. Gilteritinib: First Global Approval. Dhillon S Drugs; 2019 Feb; 79(3):331-339. PubMed ID: 30721452 [TBL] [Abstract][Full Text] [Related]
13. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Smith CC; Levis MJ; Perl AE; Hill JE; Rosales M; Bahceci E Blood Adv; 2022 Apr; 6(7):2144-2155. PubMed ID: 35130342 [TBL] [Abstract][Full Text] [Related]
14. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory Short NJ; Daver N; Dinardo CD; Kadia T; Nasr LF; Macaron W; Yilmaz M; Borthakur G; Montalban-Bravo G; Garcia-Manero G; Issa GC; Chien KS; Jabbour E; Nasnas C; Huang X; Qiao W; Matthews J; Stojanik CJ; Patel KP; Abramova R; Thankachan J; Konopleva M; Kantarjian H; Ravandi F J Clin Oncol; 2024 May; 42(13):1499-1508. PubMed ID: 38277619 [TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. Perl AE; Hosono N; Montesinos P; Podoltsev N; Martinelli G; Panoskaltsis N; Recher C; Smith CC; Levis MJ; Strickland S; Röllig C; Groß-Langenhoff M; Chou WC; Lee JH; Yokoyama H; Hasabou N; Lu Q; Tiu RV; Altman JK Blood Cancer J; 2022 May; 12(5):84. PubMed ID: 35637252 [TBL] [Abstract][Full Text] [Related]
16. [Gilteritinib for pediatric FLT3 internal tandem duplication-positive recurrent acute myeloid leukemia]. Fukuoka K; Tsumura Y; Noguchi J; Sugawa M; Takaki T; Hiraki T; Inoue K; Mitani Y; Tomita O; Oshima K; Yanagi M; Isobe K; Mori M; Arakawa Y; Koh K Rinsho Ketsueki; 2020; 61(4):322-326. PubMed ID: 32378574 [TBL] [Abstract][Full Text] [Related]
17. Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients. Reed DR; Sen JM; Pierce EJ; Elsarrag RZ; K Keng M J Oncol Pharm Pract; 2020 Jul; 26(5):1200-1212. PubMed ID: 32338136 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594 [TBL] [Abstract][Full Text] [Related]